Create a living biobank of PDOs from Stage I-III lung cancer patients.
Read, consented to and signed the IRB-approved informed consent form prior to any study related procedure.
Diagnosis of lung cancer or lung mass or lymphadenopathy that will either systemic treatment or tumor resection as part of standard of care
Any clinical stage of lung cancer
Adult patients ≥18 years of age
At the discretion of the treating physician, patient will not be able to fulfill the requirements of the study.
Lung cancer patients
Other
Prospective
Lung Tumor Resection
Procedure/SurgeryLung Tumor Resection
To establish and characterize a biobank of patient-derived organoids (PDOs), and investigate the potential of PDOs to recapitulate ex vivo responses to chemotherapeutic and targeted agents observed in the clinic.
Establishment of a living biobank of PDOs and the potential of PDOs to repeat their process outside a living organism
Correlation of PDO and Circulating tumor cells (CTCs)
To establish a connection between PDOs and CTCs, and their relationship to cancer
Click on the lead sponsor to view all of their trials.
The University of Texas Health Science Center at San Antonio
Lead sponsor
National Cancer Institute (NCI)
Collaborator
